In this study, we expanded our clinical samples, collected 75 de novo AML [non-acute promyelocytic leukemia (non-APL)], and detected the methylation degree of SPRED1 and its correlation with treatment response and long-term survival. Here, SPRED1 is linked to acute myeloid leukemia.